Ibuprofen children cystic fibrosis pharmacokinetics adverse effects Antiinflammatory therapy ibuprofen progression lund disease cystic fibrosis CF pharmacokinetics toxicity ibuprofen randomized double-blind placebo-controlled dose-escalation study children CF years age subjects mg drug first month mg second month mg third month Ibuprofen pharmacokinetics evaluation adverse effects beginning end month dose ibuprofen peak plasma concentration Cmax micrograms/ml blind nature study dose matched subjects placebo subjects ibuprofen months treatment subjects months dose escalation Cmax area concentration-time curve pharmacokinetics ibuprofen children CF mg/kg mean SD healthy children similar dose Peak plasma concentration micrograms/ml area concentration-time curve mg.min/ml apparent total clearance apparent volume distribution terminal phase ml/kg children CF Time Cmax minutes elimination half-life minutes different subjects study side effects adverse effects Thus ibuprofen administration significant toxic effects Cmax effective dosing patients CF 